SG3 Management’s Milestone Pharmaceuticals MIST Stock Holding History

SG3 Management’s Portfolio MIST Stock Details MIST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-5,000	Closed	-$37K	–	1146
2020 Q3	$37K	Buy	+5,000	New	+$35.8K	﹤0.01%	835

Other funds holding MIST

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Millennium Management

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SG3 Management's MIST Position: Q4 2020 in Review

SG3 Management sold out of Milestone Pharmaceuticals (MIST) in Q4 2020, closing a stake of 5,000 shares — an estimated $37K sold.

SG3 Management first reported a position in MIST in Q3 2020 and held it in 1 quarter. The position peaked at $37K in Q3 2020. 34 funds tracked by Wall St. Rank hold MIST as of Q4 2020.

SG3 Management reported no remaining Milestone Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
SG3 Management sold 5,000 Milestone Pharmaceuticals shares in Q4 2020, an estimated $37K.
SG3 Management first reported a position in Milestone Pharmaceuticals in Q3 2020 and held it in 1 quarter.
SG3 Management's Milestone Pharmaceuticals position peaked at $37K in Q3 2020.
34 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q4 2020.

Based on SG3 Management's 13F filing for Q4 2020, filed 16 Feb 2021.